IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients
Author
dc.contributor.author
Venegas, Mauricio
Author
dc.contributor.author
Villanueva, Rodrigo A.
Author
dc.contributor.author
González, Katherine
Author
dc.contributor.author
Brahm Barril, Javier
Admission date
dc.date.accessioned
2019-03-11T13:02:24Z
Available date
dc.date.available
2019-03-11T13:02:24Z
Publication date
dc.date.issued
2011
Cita de ítem
dc.identifier.citation
World Journal of Gastroenterology, Volumen 17, Issue 31, 2018, Pages 3636-3639
Identifier
dc.identifier.issn
10079327
Identifier
dc.identifier.other
10.3748/wjg.v17.i31.3636
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165346
Abstract
dc.description.abstract
AIM: To analyze the association of three IL28B single nucleotide polymorphisms with response to therapy in Chilean patients infected with hepatitis C virus (HCV)). METHODS: We studied two groups of patients with chronic HCV infection (genotype 1), under standard combined treatment with pegylated interferon plus ribavirin. One group consisted of 50 patients with sustained virological response, whereas the second group consisted of 49 null responders. In order to analyze the IL28B single nucleotide polymorphisms rs12979860, rs12980275 and rs8099917, samples were used for polymerase chain reaction amplification, and the genotyping was performed by restriction fragment length polymorphism. RESULTS: The IL28B rs12979860 CC, rs12980275 AA and rs8099917 TT genotypes were much more frequently found in patients with sustained virological response compared to null responders (38%, 44% and 50% vs 2%, 8.2% and 8.2%, respectively). These differences were highly significant in all three cases (P < 0